PROVE-HF Biomarker Improvement Algorithm (PROVE-HF Calculator)

Clinical calculation support · Verify results before clinical use

Biomarker change assessment

Compare NT-proBNP at baseline and follow-up. Enter LVEF at baseline for clinical context; this tool does not predict an individual follow-up LVEF.

PROVE-HF context

Use the measurement obtained before or at the start of the treatment period being assessed.

pg/mL

Enter the follow-up result and consider the time interval, clinical state, renal function, rhythm, and treatment changes when interpreting it.

pg/mL

Recorded for context only; the published PROVE-HF findings do not support calculating an individual LVEF change from these two NT-proBNP values alone.

%
Reset calculator

About PROVE-HF

PROVE-HF was a prospective, open-label, single-arm study that evaluated associations between changes in NT-proBNP after initiation of sacubitril/valsartan and changes in cardiac structure and function in patients with heart failure with reduced ejection fraction.

Among 794 enrolled participants, median NT-proBNP decreased from 816 pg/mL at baseline to 455 pg/mL at 12 months. Mean LVEF increased from 28.2% to 37.8%, an absolute increase of 9.4 percentage points. The change in log₂ NT-proBNP correlated with change in LVEF (r = −0.381).

How this calculator works

  • Percentage change = [(follow-up − baseline) ÷ baseline] × 100.
  • Absolute change = follow-up − baseline, in pg/mL.
  • Ratio = follow-up ÷ baseline.
  • Log₂ fold change = log₂(follow-up ÷ baseline).

Interpretation and limitations

A fall in NT-proBNP can be consistent with improvement, but must be interpreted alongside symptoms, signs, renal function, rhythm, volume status, treatment, and measurement timing. The study was single-arm and its correlations were not designed as a calibrated individual prediction model. This calculator therefore does not estimate LVEF change, mortality, or treatment benefit.

Reference

Januzzi JL Jr, Prescott MF, Butler J, et al.; PROVE-HF Investigators.Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085–1095. doi:10.1001/jama.2019.12821.Read the publication (DOI) · PubMed PMID: 31475295 · Free full text

Study registration: ClinicalTrials.gov NCT02887183.

Clinical disclaimer: This tool provides arithmetic summaries of NT-proBNP change and educational context from a published cohort. It is not a validated clinical prediction rule and should not be used as the sole basis for diagnosis, prognosis, or treatment decisions. Verify measurements and apply clinical judgement to the individual patient.